Lupin Receives EIR from U. S. FDA for its Somerset Manufacturing Facility

Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its manufacturing facility in Somerset, New Jersey, for the inspection conducted from January 27 to January 31, 2025.

"We are very pleased to have received the EIR for our Somerset facility. This milestone underscores our commitment to upholding the highest standards of quality and compliance, solidifying our position as a leading pharmaceutical manufacturer," said Nilesh Gupta, Managing Director, Lupin.

Shares of Lupin Limited was last trading in BSE at Rs. 1906.15 as compared to the previous close of Rs. 1977.60. The total number of shares traded during the day was 12757 in over 1667 trades.

The stock hit an intraday high of Rs. 1994.95 and intraday low of 1902.60. The net turnover during the day was Rs. 24630074.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 USFDA EIR Somerset ManufacturingFacility